PLUS THERAPEUTICS Inc

Financials

Overview Relatórios Statistics Dividends

Cash from operating activities 3.64 M1.26 M6.2 M5.8 M2.5 M 15.76 M Cash from investing activities 9 000-64 K3.56 M-2.48 M-851 K 159 K Cash from financing activities 0012.4 M2.8 M12.31 M 27.51 M Free cash flow 3.62 M1.25 M6.2 M5.79 M2.47 M 15.71 M

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecular diagnostic service, CNSide®.

Notícias

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates

Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial Offering - Slideshow (NASDAQ:PSTV) 2026-01-30

PSTV

Financials